BACKGROUND: Radiation-induced sarcoma (RIS) is a rare late complication of therapeutic irradiation with a reputation for aggressive pathology and poor outcome. METHODS: We retrospectively reviewed histopathological features, surgery and outcome in 67 patients with RIS treated between 1990 and 2005 at a single tertiary referral center. RESULTS: Previous breast cancer was the most common indication for radiotherapy. The median interval from irradiation to development of RIS of was 11 years (3-36 years). Median tumour size was 7 cm with 56% classified as high grade, 31% intermediate grade and 13% low grade. The commonest histology was leiomyosarcoma. The only relationship for histology with site was for angiosarcoma (n=9), all of which developed on the chest wall/breast after irradiation for breast cancer. Of 67 patients, 34 underwent potentially curative surgery, and microscopically clear margins were achieved in 75% of cases. Pedicled or free tissue transfer was required in 12 patients and abdominal or chest wall mesh reconstructions were required in 8 patients. No patient received adjuvant radiotherapy but 7 received adjuvant/neoadjuvant chemotherapy. Median follow up is 53 months. Median sarcoma specific survival was 54 months (2- & 5-year survival: 75% & 45%). The local relapse rate was 65%. Negative histopathological margins were a significant predictor of sarcoma specific survival (HR 3.0 95% CI 1.1-8.6 p=0.04). Grade and size of tumour approached, but did not attain significance. CONCLUSION: RIS is a biologically aggressive tumour with high rates of local relapse despite aggressive attempts at curative surgery.
BACKGROUND: Radiation-induced sarcoma (RIS) is a rare late complication of therapeutic irradiation with a reputation for aggressive pathology and poor outcome. METHODS: We retrospectively reviewed histopathological features, surgery and outcome in 67 patients with RIS treated between 1990 and 2005 at a single tertiary referral center. RESULTS: Previous breast cancer was the most common indication for radiotherapy. The median interval from irradiation to development of RIS of was 11 years (3-36 years). Median tumour size was 7 cm with 56% classified as high grade, 31% intermediate grade and 13% low grade. The commonest histology was leiomyosarcoma. The only relationship for histology with site was for angiosarcoma (n=9), all of which developed on the chest wall/breast after irradiation for breast cancer. Of 67 patients, 34 underwent potentially curative surgery, and microscopically clear margins were achieved in 75% of cases. Pedicled or free tissue transfer was required in 12 patients and abdominal or chest wall mesh reconstructions were required in 8 patients. No patient received adjuvant radiotherapy but 7 received adjuvant/neoadjuvant chemotherapy. Median follow up is 53 months. Median sarcoma specific survival was 54 months (2- & 5-year survival: 75% & 45%). The local relapse rate was 65%. Negative histopathological margins were a significant predictor of sarcoma specific survival (HR 3.0 95% CI 1.1-8.6 p=0.04). Grade and size of tumour approached, but did not attain significance. CONCLUSION: RIS is a biologically aggressive tumour with high rates of local relapse despite aggressive attempts at curative surgery.
Authors: Jeremiah R Long; Maziyar A Kalani; Krista A Goulding; Jonathan B Ashman; Jonathan A Flug Journal: Skeletal Radiol Date: 2022-05-10 Impact factor: 2.199
Authors: Christopher Conlon; Lauren Pupa; Edward M Reece; Carrie K Chu; Jessie Z Yu; Joshua Vorstenbosch; Sebastian Winocour Journal: Semin Plast Surg Date: 2021-07-06 Impact factor: 2.195
Authors: E Styring; J Seinen; M Dominguez-Valentin; H A Domanski; M Jönsson; F V von Steyern; H J Hoekstra; A J H Suurmeijer; M Nilbert Journal: Br J Cancer Date: 2014-07-01 Impact factor: 7.640
Authors: Kyung Su Kim; Ji Hyun Chang; Noorie Choi; Han-Soo Kim; Ilkyu Han; Kyung Chul Moon; Il Han Kim; Hak Jae Kim Journal: Cancer Res Treat Date: 2015-09-09 Impact factor: 4.679
Authors: Min Wook Joo; Yong Koo Kang; Koichi Ogura; Shintaro Iwata; June Hyuk Kim; Won Ju Jeong; Xiaohui Niu; Pramod S Chinder; Han Soo Kim; Sung Wook Seo; Yang-Guk Chung Journal: PLoS One Date: 2018-10-17 Impact factor: 3.240
Authors: Samuli H Salminen; Mika M Sampo; Tom O Böhling; Laura Tuomikoski; Maija Tarkkanen; Carl P Blomqvist Journal: Cancer Med Date: 2018-07-25 Impact factor: 4.452